These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

841 related articles for article (PubMed ID: 18251359)

  • 1. Endocrine modifications associated with final oocyte maturation with gonadotropin-releasing hormone agonists vs. human chorionic gonadotropin in women undergoing intrauterine insemination.
    Díaz I; Guillén A; Pacheco A; Requena A; Garcia-Velasco JA
    J Reprod Med; 2008 Jan; 53(1):33-9. PubMed ID: 18251359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
    Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
    Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
    Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
    Kolibianakis EM; Schultze-Mosgau A; Schroer A; van Steirteghem A; Devroey P; Diedrich K; Griesinger G
    Hum Reprod; 2005 Oct; 20(10):2887-92. PubMed ID: 15979994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction.
    Andersen CY; Humaidan P; Ejdrup HB; Bungum L; Grøndahl ML; Westergaard LG
    Hum Reprod; 2006 Aug; 21(8):2126-30. PubMed ID: 16682403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human chorionic gonadotropin administration is associated with high pregnancy rates during ovarian stimulation and timed intercourse or intrauterine insemination.
    Mitwally MF; Abdel-Razeq S; Casper RF
    Reprod Biol Endocrinol; 2004 Jul; 2():55. PubMed ID: 15239837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone.
    Kolibianakis EM; Papanikolaou EG; Tournaye H; Camus M; Van Steirteghem AC; Devroey P
    Fertil Steril; 2007 Nov; 88(5):1382-8. PubMed ID: 17445806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LH (as HCG) and FSH surges for final oocyte maturation: sometimes it takes two to tango?
    Kol S; Humaidan P
    Reprod Biomed Online; 2010 Nov; 21(5):590-2. PubMed ID: 20851052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and endocrine effects of ovulation induction with FSH and hCG supplementation in low responders in the midfollicular phase. A pilot study.
    Ferrari B; Barusi L; Coppola F
    J Reprod Med; 2002 Feb; 47(2):137-43. PubMed ID: 11883353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early and late hormonal responses to the microdose gonadotropin-releasing hormone agonist in normal menstruating women.
    Park WI; Kim SS; Chung HR; Shin SY; Lee JY
    Fertil Steril; 2004 Apr; 81(4):1067-72. PubMed ID: 15066465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of daily and alternate day recombinant follicle-stimulating hormone stimulation protocols for intrauterine insemination.
    Kabli N; Sylvestre C; Tulandi T; Buckett W
    Fertil Steril; 2009 Apr; 91(4):1141-4. PubMed ID: 18342857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
    Papanikolaou EG; Bourgain C; Kolibianakis E; Tournaye H; Devroey P
    Hum Reprod; 2005 Jun; 20(6):1541-7. PubMed ID: 15705618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovulation triggering in clomiphene citrate-stimulated cycles: human chorionic gonadotropin versus a gonadotropin releasing hormone agonist.
    Schmidt-Sarosi C; Kaplan DR; Sarosi P; Essig MN; Licciardi FL; Keltz M; Levitz M
    J Assist Reprod Genet; 1995 Mar; 12(3):167-74. PubMed ID: 8520180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of human chorionic gonadotropin as a replacement for gonadotropin-releasing hormone in ovulation-synchronization protocols before fixed timed artificial insemination in beef cattle.
    Burns MG; Buttrey BS; Dobbins CA; Martel CA; Olson KC; Lamb GC; Stevenson JS
    J Anim Sci; 2008 Oct; 86(10):2539-48. PubMed ID: 18539821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homologous intrauterine insemination in controlled ovarian hyperstimulation cycles: a comparison among three different regimens.
    Casadei L; Zamaro V; Calcagni M; Ticconi C; Dorrucci M; Piccione E
    Eur J Obstet Gynecol Reprod Biol; 2006 Dec; 129(2):155-61. PubMed ID: 16687201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.